deltatrials
Completed PHASE3 NCT00090753

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia

Sponsor: Hoffmann-La Roche

Conditions Anemia
Interventions Darbepoetin alfa Epoetin alfa Epoetin beta Methoxy Polyethylene Glycol-Epoetin Beta
Updated 7 times since 2017 Last updated: Feb 10, 2012 Started: Oct 31, 2004 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This PHASE3 trial investigates Anemia and is currently completed. Hoffmann-La Roche leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain, Aalborg, Denmark, Aalst, Belgium, Aarau, Switzerland, Albuquerque, United States, Alcorcón, Spain, Alexandroupoli, Greece, Alicante, Spain, Allentown, United States, Almería, Spain and 209 more location s